vs

Side-by-side financial comparison of Blend Labs, Inc. (BLND) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $32.4M, roughly 1.1× Blend Labs, Inc.). Blend Labs, Inc. runs the higher net margin — -7.8% vs -304.2%, a 296.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 7.6%). Blend Labs, Inc. produced more free cash flow last quarter ($-21.0K vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 16.6%).

GU Energy Labs is a company based in Berkeley, California, that produces sports nutrition products, most notably energy gels. Often consumed during endurance events, the gels are designed to be quickly and easily digested during any type of activity. Other products include energy chews, drink mixes, hydration tablets, stroopwafels and a Roctane line that includes an energy drink mix, protein recovery drink mix, gel, and capsules. The company was founded in 1994 by Bill Vaughan, who began crea...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BLND vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$32.4M
BLND
Growing faster (revenue YoY)
RXRX
RXRX
+674.1% gap
RXRX
681.7%
7.6%
BLND
Higher net margin
BLND
BLND
296.4% more per $
BLND
-7.8%
-304.2%
RXRX
More free cash flow
BLND
BLND
$47.3M more FCF
BLND
$-21.0K
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
16.6%
BLND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLND
BLND
RXRX
RXRX
Revenue
$32.4M
$35.5M
Net Profit
$-2.5M
$-108.1M
Gross Margin
75.7%
59.8%
Operating Margin
-11.1%
-304.8%
Net Margin
-7.8%
-304.2%
Revenue YoY
7.6%
681.7%
Net Profit YoY
-207.0%
39.6%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLND
BLND
RXRX
RXRX
Q4 25
$32.4M
$35.5M
Q3 25
$32.7M
$5.2M
Q2 25
$31.6M
$19.2M
Q1 25
$26.8M
$14.7M
Q4 24
$30.1M
$4.5M
Q3 24
$33.1M
$26.1M
Q2 24
$28.7M
$14.4M
Q1 24
$23.8M
$13.8M
Net Profit
BLND
BLND
RXRX
RXRX
Q4 25
$-2.5M
$-108.1M
Q3 25
$12.1M
$-162.3M
Q2 25
$-6.8M
$-171.9M
Q1 25
$-9.5M
$-202.5M
Q4 24
$-825.0K
$-178.9M
Q3 24
$-2.4M
$-95.8M
Q2 24
$-19.4M
$-97.5M
Q1 24
$-20.7M
$-91.4M
Gross Margin
BLND
BLND
RXRX
RXRX
Q4 25
75.7%
59.8%
Q3 25
74.3%
-183.8%
Q2 25
73.8%
-4.9%
Q1 25
70.8%
-48.0%
Q4 24
74.2%
-181.4%
Q3 24
74.0%
53.7%
Q2 24
70.9%
36.2%
Q1 24
67.3%
19.1%
Operating Margin
BLND
BLND
RXRX
RXRX
Q4 25
-11.1%
-304.8%
Q3 25
-16.4%
-3327.6%
Q2 25
-15.3%
-916.8%
Q1 25
-29.7%
-1297.9%
Q4 24
-10.9%
-4042.4%
Q3 24
-34.1%
-377.1%
Q2 24
-45.5%
-697.4%
Q1 24
-89.0%
-698.4%
Net Margin
BLND
BLND
RXRX
RXRX
Q4 25
-7.8%
-304.2%
Q3 25
37.0%
-3135.3%
Q2 25
-21.6%
-894.2%
Q1 25
-35.5%
-1373.3%
Q4 24
-2.7%
-3935.5%
Q3 24
-7.4%
-367.5%
Q2 24
-67.6%
-676.6%
Q1 24
-86.7%
-662.4%
EPS (diluted)
BLND
BLND
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$0.02
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.03
$-0.56
Q3 24
$-0.03
$-0.34
Q2 24
$-0.09
$-0.40
Q1 24
$-0.09
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLND
BLND
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$68.3M
$743.3M
Total DebtLower is stronger
$0
$9.6M
Stockholders' EquityBook value
$-30.5M
$1.1B
Total Assets
$170.0M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLND
BLND
RXRX
RXRX
Q4 25
$68.3M
$743.3M
Q3 25
$77.3M
$659.8M
Q2 25
$88.3M
$525.1M
Q1 25
$104.8M
$500.5M
Q4 24
$94.2M
$594.4M
Q3 24
$112.3M
$427.6M
Q2 24
$108.9M
$474.3M
Q1 24
$121.1M
$296.3M
Total Debt
BLND
BLND
RXRX
RXRX
Q4 25
$0
$9.6M
Q3 25
$0
$11.9M
Q2 25
$0
$14.2M
Q1 25
$0
$16.4M
Q4 24
$0
$19.0M
Q3 24
$0
$20.5M
Q2 24
$0
$22.9M
Q1 24
$138.9M
Stockholders' Equity
BLND
BLND
RXRX
RXRX
Q4 25
$-30.5M
$1.1B
Q3 25
$-13.4M
$1.0B
Q2 25
$-23.1M
$919.1M
Q1 25
$-17.2M
$933.9M
Q4 24
$-56.4M
$1.0B
Q3 24
$-49.6M
$524.6M
Q2 24
$-45.5M
$584.4M
Q1 24
$-35.8M
$401.2M
Total Assets
BLND
BLND
RXRX
RXRX
Q4 25
$170.0M
$1.5B
Q3 25
$188.6M
$1.4B
Q2 25
$182.2M
$1.3B
Q1 25
$187.5M
$1.3B
Q4 24
$178.1M
$1.4B
Q3 24
$186.1M
$726.5M
Q2 24
$185.4M
$775.9M
Q1 24
$201.8M
$557.8M
Debt / Equity
BLND
BLND
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLND
BLND
RXRX
RXRX
Operating Cash FlowLast quarter
$1.5M
$-46.1M
Free Cash FlowOCF − Capex
$-21.0K
$-47.3M
FCF MarginFCF / Revenue
-0.1%
-133.1%
Capex IntensityCapex / Revenue
4.8%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-81.0K
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLND
BLND
RXRX
RXRX
Q4 25
$1.5M
$-46.1M
Q3 25
$-3.6M
$-117.4M
Q2 25
$-6.5M
$-76.4M
Q1 25
$20.1M
$-132.0M
Q4 24
$-4.6M
$-115.4M
Q3 24
$2.1M
$-59.2M
Q2 24
$-6.7M
$-82.2M
Q1 24
$-3.9M
$-102.3M
Free Cash Flow
BLND
BLND
RXRX
RXRX
Q4 25
$-21.0K
$-47.3M
Q3 25
$-5.8M
$-117.6M
Q2 25
$-10.1M
$-79.6M
Q1 25
$15.8M
$-133.8M
Q4 24
$-7.1M
$-116.7M
Q3 24
$-1.4M
$-63.8M
Q2 24
$-8.5M
$-83.4M
Q1 24
$-5.8M
$-109.0M
FCF Margin
BLND
BLND
RXRX
RXRX
Q4 25
-0.1%
-133.1%
Q3 25
-17.6%
-2272.5%
Q2 25
-31.9%
-413.9%
Q1 25
58.9%
-907.4%
Q4 24
-23.5%
-2567.7%
Q3 24
-4.1%
-244.6%
Q2 24
-29.7%
-578.5%
Q1 24
-24.5%
-789.9%
Capex Intensity
BLND
BLND
RXRX
RXRX
Q4 25
4.8%
3.5%
Q3 25
6.5%
4.7%
Q2 25
11.4%
16.4%
Q1 25
16.1%
12.4%
Q4 24
8.3%
28.6%
Q3 24
10.4%
17.5%
Q2 24
6.5%
8.2%
Q1 24
8.2%
48.2%
Cash Conversion
BLND
BLND
RXRX
RXRX
Q4 25
Q3 25
-0.30×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLND
BLND

Mortgage Suite$18.9M58%
Consumer Banking Suite$11.4M35%
Professional Services$2.1M6%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons